Back

Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: A subanalysis from the DEDICATE-DZHK6 trial

1 September 2024 (09:11 - 09:22)
Organised by: Logo
Congress Presentation Part of: Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Sabine Bleiziffer

Heart Centre Central Clinic Bad Berka, Bad Berka (Germany)

7 More presentations in this session

Presentation thumbnail
Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Doctor J. Spertus (Kansas City, US)
Slides Video
Presentation thumbnail
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Doctor S. Hegde (Dallas, US)
Slides Video
Presentation thumbnail
Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis
Associate Professor M. Banovic (Belgrade, RS)
Slides Video

Access the full session

Session thumbnail
Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 09:11 CET
You may be interested in
thumbnail
Congress Presentation
Sex-specific considerations of TAVI
thumbnail
Congress Session
Aortic stenosis in females: the impact of the RHEIA trial on clinical practice
thumbnail
Congress Presentation
Sex related differences in frequency, management and outcome of severe native valvular heart disease. Results from the ESC-EORP Valvular Heart Disease II survey

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources